Adaptimmune Therapeutics plc - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 2830 www.adaptimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - Jul 3rd, 2025 9:02 am
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - Jun 30th, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week - Jun 27th, 2025 9:01 am
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - Jun 26th, 2025 9:00 am
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls - Jun 26th, 2025 7:49 am
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading - Jun 25th, 2025 9:04 am
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading - Jun 23rd, 2025 9:14 am
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - Jun 17th, 2025 9:03 am
Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ... - May 14th, 2025 1:05 am
Adaptimmune Reports Q1 Financial Results and Provides Business Update - May 13th, 2025 5:30 am
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 - May 7th, 2025 10:00 am
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story - Mar 25th, 2025 3:26 am
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ... - Mar 21st, 2025 1:01 am
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options - Mar 20th, 2025 6:05 am
Adaptimmune Provides Q4 and Full Year 2024 Business Update - Mar 20th, 2025 5:00 am
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Mar 18th, 2025 5:00 am
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025 - Mar 12th, 2025 2:54 pm
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds - Mar 4th, 2025 3:39 am
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Jan 30th, 2025 2:00 pm
Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago - Jan 22nd, 2025 5:20 am